Background/Objectives: Gallbladder cancer (GBC) is highly prevalent in Western Argentina, where the frequency and clinical significance of HER2/ERBB2 abnormalities remain unknown. We investigated the prevalence, prognostic impact, and genomic co-occurrence of HER2/ERBB2 alterations in Argentine patients with GBC. Metho...
G. F. Arroyo, Gabriela Acosta Haab, Aylén Avila et al.· Cancers· 0 citations
LVI and LN involvement were independently associated with worse OS and the use of AT in patients with persistent LVI and LN involvement was not associated with improved OS after NAT.
Valerie L. Armstrong, Yu-Hui H. Chang, C. Stucky et al.· Journal of Surgical Oncology· 0 citations
Pancreatic cancer is associated with high morbidity and mortality. Gemcitabine plus nab-paclitaxel (GA), along with FOLFIRINOX and NALIRIFOX, is a standard first-line treatment for advanced/metastatic pancreatic ductal adenocarcinoma (mPDAC). However, the standard GA schedule (days 1, 8, and 15 of a 28-day cycle)...
C. Hoyek, C. Eslinger, Angelo Pirozzi et al.· BMC Cancer· 0 citations
Futibatinib plus pembrolizumab demonstrated an acceptable safety profile but did not meet efficacy thresholds supporting further study in FGF19-expressing HCC, an unmet need after first-line immunotherapy.
Nguyen H. Tran, M. Palmer, Angela Ulrich et al.· The Oncologist· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.